OncoMatch/Clinical Trials/NCT07094048

Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager

Is NCT07094048 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Target trough IgG level of 8-10 g/L and Target trough IgG level 4-6 g/L for multiple myeloma refractory.

Treatment: Target trough IgG level of 8-10 g/L · Target trough IgG level 4-6 g/L · No history of recurrent or severe infections and total IgG level higher or equal at 4 g/L — Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.